Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Shield Therapeutics Awarded AIM Listing of the Year at Biotech and Money Awards

9 Sep 2016

London, UK, 08 September 2016: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that it received the ‘AIM listing of the Year Award 2016’ at the Biotech and Money Assembly and Awards.

Carl Sterritt, Founder and Chief Executive Officer, commented: “We are delighted to have won the award for ‘AIM listing of the Year’, especially among a group of worthy peers. This award recognises the hard work and vision of the Shield Therapeutics team and the strong support of our shareholders, which together have made this year a successful and dynamic one.”

Ends –

For further information please contact:

Shield Therapeutics plc +44 (0)191 511 8507
Carl Sterritt, Chief Executive Officer
Richard Jones, Chief Financial Officer

Liberum Capital Limited
Christopher Britton
Steve Pearce
+44 (0)20 3100 2222
Financial PR Advisor
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott
Matthew Neal
Lindsey Neville
Hendrik Thys

About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE’s AIM under the ticker STX. For more information please visit

To download this release in pdf format please click here.

Back to news